This study looks at the real-world use of an academically produced anti-CD19 CAR-T cell therapy in people with relapsed or treatment-resistant B-cell lymphoma. Adults aged 18 and over with confirmed CD19 expression in their tumor tissue who have received at least one prior line of treatment may take part. It is a study without a phase and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * age ≥18 years, * relapsed or refractory LBCL, * confirmed CD19 expression in tumor tissue, * prior exposure to at least one line of anti-tumor therapy Exclusion Criteria: * pregnancy, * active hepatitis B or C infection, HIV infection, * naïve T-lymphocyte count (CD3+CCR7+CD45RO-) ≤ 0,5%